101 related articles for article (PubMed ID: 6977499)
1. Tumor immunity to murine plasma cell tumors. VII. Expression of H-2 and tumor antigens on Ig synthesis variants of MPC-11.
Giorgi JV; Burton RC; Scott D; Warner NL
Int J Cancer; 1982 Jan; 29(1):119-26. PubMed ID: 6977499
[TBL] [Abstract][Full Text] [Related]
2. Continuous cytotoxic T cell lines reactive against murine plasmacytoma tumor-associated antigens.
Giorgi JV; Warner NL
J Immunol; 1981 Jan; 126(1):322-30. PubMed ID: 6161166
[TBL] [Abstract][Full Text] [Related]
3. Tumor immunity to murine plasma cell tumors. V. Genetic control of the in vitro cytotoxic T-cell response to plasma cell tumor-associated antigens of NZB mice.
Burton RC; Warner NL
J Natl Cancer Inst; 1980 Aug; 65(2):431-40. PubMed ID: 6967529
[TBL] [Abstract][Full Text] [Related]
4. Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.
Burton RC; Warner NL
J Natl Cancer Inst; 1977 Mar; 58(3):701-9. PubMed ID: 300112
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.
Toffaletti DL; Darrow TL; Scott DW
J Immunol; 1983 Jun; 130(6):2982-6. PubMed ID: 6189910
[TBL] [Abstract][Full Text] [Related]
6. Frequency of murine cytotoxic T cell precursors reactive to plasma cell tumour-associated antigens as compared to major histocompatibility antigens.
Burton RC
Aust J Exp Biol Med Sci; 1986 Aug; 64 ( Pt 4)():323-34. PubMed ID: 3491597
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor.
Germain RN; Dorf ME; Benacerraf B
J Exp Med; 1975 Oct; 142(4):1023-8. PubMed ID: 809532
[TBL] [Abstract][Full Text] [Related]
8. Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses.
Fujiwara H; Yoshioka T; Shima J; Kosugi A; Itoh K; Hamaoka T
J Immunol; 1986 Apr; 136(7):2715-9. PubMed ID: 3005417
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
10. Immune response to Moloney murine leukemia virus nonviral, tumor-associated antigens fails to provide in vivo tumor protection.
Jiang D; Flyer DC
J Immunol; 1992 Feb; 148(3):974-80. PubMed ID: 1730885
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocyte lines reactive against murine plasmacytoma antigens: dissociation of cytotoxicity and Lyt-2 expression.
Giorgi JV; Zawadzki JA; Warner NL
Eur J Immunol; 1982 Oct; 12(10):831-7. PubMed ID: 6184236
[TBL] [Abstract][Full Text] [Related]
12. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocytes to murine plasmacytoma cells in allogeneic and syngeneic mice: H-2 antigens are essential in the induction and effector stages of CTL.
Kaneko Y; Natsuume-Sakai S; Migita S
J Immunol; 1978 Aug; 121(2):427-37. PubMed ID: 79604
[No Abstract] [Full Text] [Related]
14. In vitro induction of tumor-specific immunity. III. Lack of requirement for H-2 compatibility in lysis of tumor targets by T cells activated in vitro to oncofetal and plasmacytoma antigens.
Burton RC; Chism SE; Warner NL
J Immunol; 1977 Mar; 118(3):971-80. PubMed ID: 300394
[TBL] [Abstract][Full Text] [Related]
15. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
16. Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones.
Jones B; Tite JP; Janeway CA
J Immunol; 1986 Jan; 136(1):348-56. PubMed ID: 2415625
[TBL] [Abstract][Full Text] [Related]
17. In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.
Wagner H; Röllinghoff M
J Exp Med; 1973 Jul; 138(1):1-15. PubMed ID: 4541509
[TBL] [Abstract][Full Text] [Related]
18. Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens.
Kedar E; Bonavida B
J Immunol; 1975 Nov; 115(5):1301-8. PubMed ID: 51889
[TBL] [Abstract][Full Text] [Related]
19. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
20. Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier.
Collavo D; Parenti A; Biasi G; Chieco-Bianchi L; Colombatti A
J Natl Cancer Inst; 1978 Sep; 61(3):885-90. PubMed ID: 80457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
